GSK, Pfiz­er head in­to patent du­el in high-stakes RSV vac­cine war

A patent bat­tle is un­der­way be­tween GSK and Pfiz­er in the US, with the for­mer call­ing for a ju­ry tri­al over their re­spec­tive RSV vac­cines, both set for wide­spread launch in the fall.

In a fresh law­suit, GSK is al­leg­ing Pfiz­er in­fringed on four patents re­lat­ed to GSK’s Arexvy vac­cine, which locked in an FDA OK on May 3 in adults 60 years and over. Pfiz­er’s Abrys­vo was ap­proved on May 31.

A court doc­u­ment filed on Wednes­day at the Delaware Dis­trict Court shows the patent dis­pute re­volves around vac­cine com­po­si­tion and how they are pre­pared. Arexvy is de­signed to in­duce a re­sponse against RSVpreF3, while Abrys­vo tar­gets RSV pre F, ac­cord­ing to their re­spec­tive FDA la­bels.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.